InterMune Phase III Efforts Will Be Funded Through Infergen Sale
This article was originally published in The Pink Sheet Daily
Executive Summary
Proceeds from InterMune’s sale of the hepatitis C agent to Valeant will be used for development of idiopathic pulmonary fibrosis therapies.
You may also be interested in...
InterMune Ad Improperly Infers Infergen Superiority, FDA’s Ad Division Says
A DDMAC untitled letter accuses InterMune of overstating efficacy and omitting safety information in an ad for chronic hepatitis C therapy Infergen.
InterMune Ad Improperly Infers Infergen Superiority, FDA’s Ad Division Says
A DDMAC untitled letter accuses InterMune of overstating efficacy and omitting safety information in an ad for chronic hepatitis C therapy Infergen.
Third Time's The Charm? Oritavancin Finds New Home With Targanta
Indianapolis-based private biotech firm will take over development of the Lilly-developed Phase III antibiotic, which was previously held by InterMune.